Trial Outcomes & Findings for A Study for Participants With Major Depression (NCT NCT00420004)
NCT ID: NCT00420004
Last Updated: 2018-04-27
Results Overview
The HAMD-17 is a 17-item assessment used to assess the severity of depression and its improvement during the course of therapy. Each item was evaluated and scored using either a 5-point scale of 0 (not present/absent) to 4 (very severe) or a 3-point scale of 0 (not present/absent) to 2 (marked). Higher scores indicate greater symptom severity. The total score was the sum of the scores from HAMD-17 Items 1 through 17 and ranged from 0 (not at all depressed) to 52 (severely depressed). Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline score, treatment-by-visit, and baseline score-by-visit.
COMPLETED
PHASE2
469 participants
Baseline, Week 8
2018-04-27
Participant Flow
A total of 701 participants were included in a screening/washout period (from 3 to 30 days in duration) prior to group assignments; 232 participants discontinued during this period, and 469 participants were randomized. There was an 8-week Double-blind Phase followed by a 1-week Discontinuation Phase after abrupt discontinuation of treatment.
Participant milestones
| Measure |
LY2216684
LY2216684: flexible dose of 3, 6, 9, or 12 milligrams (mg), tablets, administered orally, once daily for 8 weeks
|
Placebo
Placebo: tablet and capsule equivalents to LY2216684 and escitalopram, respectively, administered orally, once daily for 8 weeks
|
Escitalopram
Escitalopram: flexible dose of 10 or 20 mg, capsules, administered orally, once daily for 8 weeks
|
|---|---|---|---|
|
Overall Study
STARTED
|
269
|
138
|
62
|
|
Overall Study
Received at Least 1 Dose of Study Drug
|
249
|
122
|
54
|
|
Overall Study
COMPLETED
|
140
|
67
|
30
|
|
Overall Study
NOT COMPLETED
|
129
|
71
|
32
|
Reasons for withdrawal
| Measure |
LY2216684
LY2216684: flexible dose of 3, 6, 9, or 12 milligrams (mg), tablets, administered orally, once daily for 8 weeks
|
Placebo
Placebo: tablet and capsule equivalents to LY2216684 and escitalopram, respectively, administered orally, once daily for 8 weeks
|
Escitalopram
Escitalopram: flexible dose of 10 or 20 mg, capsules, administered orally, once daily for 8 weeks
|
|---|---|---|---|
|
Overall Study
Adverse Event
|
4
|
1
|
1
|
|
Overall Study
Lack of Efficacy
|
5
|
4
|
1
|
|
Overall Study
Lost to Follow-up
|
31
|
12
|
10
|
|
Overall Study
Entry Criteria Not Met
|
0
|
1
|
0
|
|
Overall Study
Physician Decision
|
14
|
4
|
2
|
|
Overall Study
Protocol Violation
|
5
|
4
|
3
|
|
Overall Study
Withdrawal by Subject
|
67
|
42
|
14
|
|
Overall Study
Sponsor Decision
|
3
|
3
|
1
|
Baseline Characteristics
A Study for Participants With Major Depression
Baseline characteristics by cohort
| Measure |
LY2216684
n=269 Participants
LY2216684: flexible dose of 3, 6, 9, or 12 milligrams (mg), tablets, administered orally, once daily for 8 weeks
|
Placebo
n=138 Participants
Placebo: tablet and capsule equivalents to LY2216684 and escitalopram, respectively, administered orally, once daily for 8 weeks
|
Escitalopram
n=62 Participants
Escitalopram: flexible dose of 10 or 20 mg, capsules, administered orally, once daily for 8 weeks
|
Total
n=469 Participants
Total of all reporting groups
|
|---|---|---|---|---|
|
Age, Continuous
|
36.64 years
STANDARD_DEVIATION 10.21 • n=99 Participants
|
37.54 years
STANDARD_DEVIATION 10.97 • n=107 Participants
|
34.32 years
STANDARD_DEVIATION 9.66 • n=206 Participants
|
36.60 years
STANDARD_DEVIATION 10.40 • n=7 Participants
|
|
Sex: Female, Male
Female
|
130 Participants
n=99 Participants
|
65 Participants
n=107 Participants
|
22 Participants
n=206 Participants
|
217 Participants
n=7 Participants
|
|
Sex: Female, Male
Male
|
139 Participants
n=99 Participants
|
73 Participants
n=107 Participants
|
40 Participants
n=206 Participants
|
252 Participants
n=7 Participants
|
|
Race/Ethnicity, Customized
Caucasian
|
30 Participants
n=99 Participants
|
21 Participants
n=107 Participants
|
8 Participants
n=206 Participants
|
59 Participants
n=7 Participants
|
|
Race/Ethnicity, Customized
African
|
6 Participants
n=99 Participants
|
5 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
11 Participants
n=7 Participants
|
|
Race/Ethnicity, Customized
Hispanic
|
23 Participants
n=99 Participants
|
7 Participants
n=107 Participants
|
4 Participants
n=206 Participants
|
34 Participants
n=7 Participants
|
|
Race/Ethnicity, Customized
Native American
|
1 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
1 Participants
n=7 Participants
|
|
Race/Ethnicity, Customized
West Asian (Indian subcontinent)
|
209 Participants
n=99 Participants
|
105 Participants
n=107 Participants
|
50 Participants
n=206 Participants
|
364 Participants
n=7 Participants
|
|
Region of Enrollment
United States
|
39 Participants
n=99 Participants
|
23 Participants
n=107 Participants
|
8 Participants
n=206 Participants
|
70 Participants
n=7 Participants
|
|
Region of Enrollment
Romania
|
7 Participants
n=99 Participants
|
4 Participants
n=107 Participants
|
1 Participants
n=206 Participants
|
12 Participants
n=7 Participants
|
|
Region of Enrollment
India
|
208 Participants
n=99 Participants
|
105 Participants
n=107 Participants
|
50 Participants
n=206 Participants
|
363 Participants
n=7 Participants
|
|
Region of Enrollment
Mexico
|
15 Participants
n=99 Participants
|
6 Participants
n=107 Participants
|
3 Participants
n=206 Participants
|
24 Participants
n=7 Participants
|
PRIMARY outcome
Timeframe: Baseline, Week 8Population: All randomized participants who received at least one dose of double-blind study drug and who had a baseline and at least one post-baseline HAMD-17 value.
The HAMD-17 is a 17-item assessment used to assess the severity of depression and its improvement during the course of therapy. Each item was evaluated and scored using either a 5-point scale of 0 (not present/absent) to 4 (very severe) or a 3-point scale of 0 (not present/absent) to 2 (marked). Higher scores indicate greater symptom severity. The total score was the sum of the scores from HAMD-17 Items 1 through 17 and ranged from 0 (not at all depressed) to 52 (severely depressed). Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline score, treatment-by-visit, and baseline score-by-visit.
Outcome measures
| Measure |
LY2216684
n=248 Participants
LY2216684: flexible dose of 3, 6, 9, or 12 milligrams (mg), tablets, administered orally, once daily for 8 weeks
|
Placebo
n=122 Participants
Placebo: tablet and capsule equivalents to LY2216684 and escitalopram, respectively, administered orally, once daily for 8 weeks
|
Escitalopram
n=54 Participants
Escitalopram: flexible dose of 10 or 20 mg, capsules, administered orally, once daily for 8 weeks
|
|---|---|---|---|
|
Change From Baseline to Week 8 in the 17-item Hamilton Depression Rating Scale (HAMD-17) Total Score
|
-13.2 units on a scale
Standard Error 0.53
|
-12.6 units on a scale
Standard Error 0.74
|
-14.7 units on a scale
Standard Error 1.14
|
SECONDARY outcome
Timeframe: Baseline, Week 8Population: All randomized participants who received at least one dose of double-blind study drug and who had a baseline and at least one post-baseline Maier-Philipp subscale value.
The HAMD-17 is a 17-item assessment used to assess the severity of depression and its improvement during the course of therapy. Each item was evaluated and scored using either a 5-point scale of 0 (not present/absent) to 4 (very severe) or a 3-point scale of 0 (not present/absent) to 2 (marked). Higher scores indicate greater symptom severity. The Maier-Phillip subscale of the HAMD-17 represents the 6 "core" symptoms of depression (items: 1=depressed mood, 2=feelings of guilt, 7=work and activities, 8=retardation, 9=agitation, 10=anxiety/psychic). The subscale scores range from 0 (normal) to 24 (severe). Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline score, treatment-by-visit, and baseline score-by-visit.
Outcome measures
| Measure |
LY2216684
n=248 Participants
LY2216684: flexible dose of 3, 6, 9, or 12 milligrams (mg), tablets, administered orally, once daily for 8 weeks
|
Placebo
n=122 Participants
Placebo: tablet and capsule equivalents to LY2216684 and escitalopram, respectively, administered orally, once daily for 8 weeks
|
Escitalopram
n=54 Participants
Escitalopram: flexible dose of 10 or 20 mg, capsules, administered orally, once daily for 8 weeks
|
|---|---|---|---|
|
Change From Baseline to Week 8 in Maier-Philipp Subscale of the 17-item Hamilton Depression Rating Scale (HAMD-17)
|
-6.7 units on a scale
Standard Error 0.26
|
-6.2 units on a scale
Standard Error 0.36
|
-7.6 units on a scale
Standard Error 0.55
|
SECONDARY outcome
Timeframe: Baseline, up to Week 8Population: All randomized participants who received at least one dose of double-blind study drug and who had a baseline and at least one post-baseline HAMD-17 total score value. Last observation carried forward (LOCF) methodology was used.
A participant meets response criteria if there is at least a 50% reduction in the 17-item Hamilton Depression Rating Scale (HAMD-17) total score from baseline to the last observation carried forward (LOCF) endpoint visit. A participant meets remission criteria if the HAMD-17 total score is less than or equal to 7 at the LOCF endpoint visit. The percent of participants meeting criteria is summarized. HAMD-17 is a 17-item assessment used to assess the severity of depression and its improvement during the course of therapy. Each item was evaluated and scored using either a 5-point scale of 0 (not present/absent) to 4 (very severe) or a 3-point scale of 0 (not present/absent) to 2 (marked). Higher scores indicate greater symptom severity. The total score was the sum of the scores from HAMD-17 Items 1 through 17 and ranged from 0 (not at all depressed) to 52 (severely depressed).
Outcome measures
| Measure |
LY2216684
n=248 Participants
LY2216684: flexible dose of 3, 6, 9, or 12 milligrams (mg), tablets, administered orally, once daily for 8 weeks
|
Placebo
n=122 Participants
Placebo: tablet and capsule equivalents to LY2216684 and escitalopram, respectively, administered orally, once daily for 8 weeks
|
Escitalopram
n=54 Participants
Escitalopram: flexible dose of 10 or 20 mg, capsules, administered orally, once daily for 8 weeks
|
|---|---|---|---|
|
Response and Remission Rates
Remission
|
38.7 percentage of participants
|
31.1 percentage of participants
|
42.6 percentage of participants
|
|
Response and Remission Rates
Response
|
54.0 percentage of participants
|
48.4 percentage of participants
|
53.7 percentage of participants
|
SECONDARY outcome
Timeframe: Week 8Population: All randomized participants who received at least one dose of double-blind study drug and who had a baseline and at least one post-baseline CGI-I value.
The Clinical Global Impression of Improvement (CGI-I) scale measures the clinician's perception of participant improvement at the time of assessment compared with the start of treatment. Scores range from 1 (very much improved) to 7 (very much worse). Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, and treatment-by-visit.
Outcome measures
| Measure |
LY2216684
n=247 Participants
LY2216684: flexible dose of 3, 6, 9, or 12 milligrams (mg), tablets, administered orally, once daily for 8 weeks
|
Placebo
n=122 Participants
Placebo: tablet and capsule equivalents to LY2216684 and escitalopram, respectively, administered orally, once daily for 8 weeks
|
Escitalopram
n=53 Participants
Escitalopram: flexible dose of 10 or 20 mg, capsules, administered orally, once daily for 8 weeks
|
|---|---|---|---|
|
Clinical Global Impression of Improvement Score at Week 8
|
2.2 units on a scale
Standard Error 0.09
|
2.3 units on a scale
Standard Error 0.12
|
2.0 units on a scale
Standard Error 0.19
|
SECONDARY outcome
Timeframe: Baseline, up to Week 8Population: All randomized participants who received at least one dose of double-blind study drug and who had a baseline and at least one post-baseline HAMA value. Last observation carried forward (LOCF) methodology was used.
The HAMA is a 14-item assessment used to assess the severity of anxiety. The investigator talked to the participant about the symptoms he or she experienced during the previous week. Each item was scored using a 5-point scale (0=not present to 4=very severe). The total score of HAMA ranged from 0 (normal) to 56 (severe). Least Squares (LS) means were adjusted for treatment, investigator, and baseline score.
Outcome measures
| Measure |
LY2216684
n=212 Participants
LY2216684: flexible dose of 3, 6, 9, or 12 milligrams (mg), tablets, administered orally, once daily for 8 weeks
|
Placebo
n=106 Participants
Placebo: tablet and capsule equivalents to LY2216684 and escitalopram, respectively, administered orally, once daily for 8 weeks
|
Escitalopram
n=44 Participants
Escitalopram: flexible dose of 10 or 20 mg, capsules, administered orally, once daily for 8 weeks
|
|---|---|---|---|
|
Change From Baseline in Hamilton Anxiety Rating Scale (HAMA) Total Score up to Week 8 Endpoint
|
-9.7 units on a scale
Standard Error 0.62
|
-9.6 units on a scale
Standard Error 0.82
|
-11.6 units on a scale
Standard Error 1.19
|
SECONDARY outcome
Timeframe: Baseline, up to Week 8Population: All randomized participants who received at least one dose of double-blind study drug and who had a baseline and at least one post-baseline SF-36 Health Status Survey value. Last observation carried forward (LOCF) methodology was used.
The SF-36 Health Status Survey is a generic, health-related scale assessing a participant's quality of life on 8 domains: general health (GH), physical functioning (PF), role-physical, role-emotional, social functioning, bodily pain, vitality, and mental health. Each domain is scored by summing the individual items (GH \[range: 5-25\]; PF \[range: 10-30\]; role-physical \[range: 4-8\]; role-emotional \[range: 3-6\]; social functioning \[range: 2-10\]; bodily pain \[range: 2-11\]; vitality \[range: 4-24\]; mental health \[range: 5-30\]) and transforming the scores into a 0 to 100 scale, with higher scores indicating better health status or functioning. Two summary scores (mental component and physical component scores) were constructed based on the 8 SF-36 domains. Mental component summary and physical component summary scores range from 0 to 100 (higher scores indicate better health status).
Outcome measures
| Measure |
LY2216684
n=192 Participants
LY2216684: flexible dose of 3, 6, 9, or 12 milligrams (mg), tablets, administered orally, once daily for 8 weeks
|
Placebo
n=99 Participants
Placebo: tablet and capsule equivalents to LY2216684 and escitalopram, respectively, administered orally, once daily for 8 weeks
|
Escitalopram
n=41 Participants
Escitalopram: flexible dose of 10 or 20 mg, capsules, administered orally, once daily for 8 weeks
|
|---|---|---|---|
|
Change From Baseline on the 36-item Short-Form (SF-36) Health Status Survey Mental and Physical Components up to Week 8 Endpoint
Mental Component Summary
|
13.4 units on a scale
Standard Deviation 13.1
|
12.6 units on a scale
Standard Deviation 13.9
|
12.4 units on a scale
Standard Deviation 12.4
|
|
Change From Baseline on the 36-item Short-Form (SF-36) Health Status Survey Mental and Physical Components up to Week 8 Endpoint
Physical Component Summary
|
4.17 units on a scale
Standard Deviation 9.00
|
2.37 units on a scale
Standard Deviation 8.26
|
2.74 units on a scale
Standard Deviation 7.65
|
SECONDARY outcome
Timeframe: Baseline, up to Week 8Population: All randomized participants who received at least one dose of double-blind study drug and who had a baseline and at least one post-baseline Quick Inventory of Depressive Symptomatology value. Last observation carried forward (LOCF) methodology was used.
The Quick Inventory of Depressive Symptomatology is a 16-item participant-rated measure of depressive symptomatology. There were 4 possible answers per question that are specific to the question; each question (Q) was scored 0 (no problems) to 3 (increased symptoms). The total score was the sum of the highest number from Q1-4, number from Q5, highest number from Q6-9, total for Q10-14, and the highest number from Q15-16. The total score ranges from 0 to 27 with higher scores indicative of greater severity of depression. Least Squares (LS) means were adjusted for treatment, investigator, and baseline score.
Outcome measures
| Measure |
LY2216684
n=198 Participants
LY2216684: flexible dose of 3, 6, 9, or 12 milligrams (mg), tablets, administered orally, once daily for 8 weeks
|
Placebo
n=103 Participants
Placebo: tablet and capsule equivalents to LY2216684 and escitalopram, respectively, administered orally, once daily for 8 weeks
|
Escitalopram
n=42 Participants
Escitalopram: flexible dose of 10 or 20 mg, capsules, administered orally, once daily for 8 weeks
|
|---|---|---|---|
|
Change From Baseline in Quick Inventory of Depressive Symptomatology Total Score up to Week 8 Endpoint
|
-10.2 units on a scale
Standard Error 0.54
|
-8.3 units on a scale
Standard Error 0.71
|
-11.6 units on a scale
Standard Error 1.04
|
SECONDARY outcome
Timeframe: Baseline, up to Week 8Population: All randomized participants who received at least one dose of double-blind study drug and who had a baseline and at least one post-baseline BSI value. Last observation carried forward (LOCF) methodology was used.
Beck Scale for Suicide Ideation (BSI) is a 21-item participant-completed questionnaire designed to assess severity of suicidal ideation in adults and adolescents. The BSI total score is calculated as the sum of the responses (rated from 0 to 2 in terms of severity) to the first 19 items of the BSI scale. The BSI total score ranges from 0 to 38, with a higher score indicating a higher degree of suicide ideation.
Outcome measures
| Measure |
LY2216684
n=245 Participants
LY2216684: flexible dose of 3, 6, 9, or 12 milligrams (mg), tablets, administered orally, once daily for 8 weeks
|
Placebo
n=122 Participants
Placebo: tablet and capsule equivalents to LY2216684 and escitalopram, respectively, administered orally, once daily for 8 weeks
|
Escitalopram
n=51 Participants
Escitalopram: flexible dose of 10 or 20 mg, capsules, administered orally, once daily for 8 weeks
|
|---|---|---|---|
|
Change From Baseline in Beck Scale for Suicide Ideation up to Week 8 Endpoint
|
-0.90 units on a scale
Standard Deviation 3.39
|
-0.54 units on a scale
Standard Deviation 2.14
|
-0.78 units on a scale
Standard Deviation 2.16
|
SECONDARY outcome
Timeframe: Baseline, up to Week 8Population: All randomized participants who received at least one dose of double-blind study drug and who had a baseline and at least one post-baseline OAS-M value. Last observation carried forward (LOCF) methodology was used.
OAS-M is a clinician-administered semistructured interview designed to assess various manifestations of aggressive behavior. Final scores are rated on 3 scales: Aggression (Agg), Irritability (Irrt), Suicidality (Suic). Agg scale has 4 subscales: Verbal Assault (Aslt), Aslt Against Objects, Aslt Against Others, Aslt Against Self; each item is scored 0-5, multiplied by the frequency of the behavior, then summed together. Agg total score is the weighted sum of the subscale scores (weights: 1=Verbal Aslt, 2=Aslt Against Objects, 3=Aslt Against Others, 4=Aslt Against Self). The Irrt scale has 2 subscales: Global Irrt, Subjective Irrt. Suic scale has 3 subscales: Suicidal Tendencies, Intent of Attempt, Lethality of Attempt. The 2 Irrt and 3 Suic subscales are rated on 6 or 7 point scales from 0=none/not at all to 6/7=very extreme. The total score ranges from 0-10 for the Irrt scale and 0-16 on the Suic scale. Least Squares means were adjusted for treatment, investigator, and baseline s
Outcome measures
| Measure |
LY2216684
n=227 Participants
LY2216684: flexible dose of 3, 6, 9, or 12 milligrams (mg), tablets, administered orally, once daily for 8 weeks
|
Placebo
n=113 Participants
Placebo: tablet and capsule equivalents to LY2216684 and escitalopram, respectively, administered orally, once daily for 8 weeks
|
Escitalopram
n=47 Participants
Escitalopram: flexible dose of 10 or 20 mg, capsules, administered orally, once daily for 8 weeks
|
|---|---|---|---|
|
Change From Baseline in Modified Overt Aggression (OAS-M) Scale up to Week 8 Endpoint
Irritability total score
|
-1.0 units on a scale
Standard Error 0.10
|
-0.9 units on a scale
Standard Error 0.14
|
-1.0 units on a scale
Standard Error 0.20
|
|
Change From Baseline in Modified Overt Aggression (OAS-M) Scale up to Week 8 Endpoint
Aggression total score
|
-4.1 units on a scale
Standard Error 0.52
|
-4.2 units on a scale
Standard Error 0.71
|
-3.9 units on a scale
Standard Error 1.06
|
|
Change From Baseline in Modified Overt Aggression (OAS-M) Scale up to Week 8 Endpoint
Suicidality total score
|
-0.2 units on a scale
Standard Error 0.04
|
-0.2 units on a scale
Standard Error 0.05
|
-0.2 units on a scale
Standard Error 0.08
|
SECONDARY outcome
Timeframe: Baseline, up to Week 8Population: All randomized participants who received at least one dose of double-blind study drug and who had a baseline and at least one post-baseline ASEX value. Last observation carried forward (LOCF) methodology was used.
The Arizona Sexual Experiences Scale (ASEX) is used to assess sexual functioning in both males and females. The ASEX total score for the male and female version is calculated as the sum of the responses (rated from 1 \[extremely\] to 6 \[no/never\]) to the 5 items of the ASEX scale. Total scores ranged from 5 to 30 with higher scores indicating greater sexual dysfunction.
Outcome measures
| Measure |
LY2216684
n=219 Participants
LY2216684: flexible dose of 3, 6, 9, or 12 milligrams (mg), tablets, administered orally, once daily for 8 weeks
|
Placebo
n=109 Participants
Placebo: tablet and capsule equivalents to LY2216684 and escitalopram, respectively, administered orally, once daily for 8 weeks
|
Escitalopram
n=43 Participants
Escitalopram: flexible dose of 10 or 20 mg, capsules, administered orally, once daily for 8 weeks
|
|---|---|---|---|
|
Change From Baseline in Arizona Sexual Experiences Scale up to Week 8 Endpoint
|
-2.68 units on a scale
Standard Deviation 6.65
|
-1.69 units on a scale
Standard Deviation 6.35
|
-1.65 units on a scale
Standard Deviation 7.43
|
SECONDARY outcome
Timeframe: Baseline, up to Week 8Population: All randomized participants who received at least one dose of double-blind study drug and who had a baseline and at least one post-baseline ISI value. Last observation carried forward (LOCF) methodology was used.
The Insomnia Severity Index (ISI) is a brief self-report instrument measuring the participant's perception of his or her insomnia. The ISI score is calculated as the sum of the responses to the 7 items of the ISI scale. Each item is rated on a 0 to 4 scale and the total score ranges from 0 to 28 with a higher score suggesting more severe insomnia.
Outcome measures
| Measure |
LY2216684
n=227 Participants
LY2216684: flexible dose of 3, 6, 9, or 12 milligrams (mg), tablets, administered orally, once daily for 8 weeks
|
Placebo
n=113 Participants
Placebo: tablet and capsule equivalents to LY2216684 and escitalopram, respectively, administered orally, once daily for 8 weeks
|
Escitalopram
n=45 Participants
Escitalopram: flexible dose of 10 or 20 mg, capsules, administered orally, once daily for 8 weeks
|
|---|---|---|---|
|
Change From Baseline in Insomnia Severity Index up to Week 8 Endpoint
|
-7.53 units on a scale
Standard Deviation 7.57
|
-7.44 units on a scale
Standard Deviation 7.73
|
-8.02 units on a scale
Standard Deviation 7.72
|
SECONDARY outcome
Timeframe: Baseline, Week 8Population: All randomized participants who received at least one dose of double-blind study drug and who had a baseline and at least one post-baseline FSS value.
Fatigue Severity Scale (FSS) is a 9-item measure of fatigue severity. Each item is scored by the participant on a scale of 1 ("Disagree") to 7 ("Agree"), with a higher score indicating a stronger agreement with the item statement regarding the participant's fatigue symptoms. The FSS total score ranges from 1 to 7, and is obtained by averaging the responses to the 9 items. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline score, treatment-by-visit, and baseline score-by-visit.
Outcome measures
| Measure |
LY2216684
n=225 Participants
LY2216684: flexible dose of 3, 6, 9, or 12 milligrams (mg), tablets, administered orally, once daily for 8 weeks
|
Placebo
n=109 Participants
Placebo: tablet and capsule equivalents to LY2216684 and escitalopram, respectively, administered orally, once daily for 8 weeks
|
Escitalopram
n=47 Participants
Escitalopram: flexible dose of 10 or 20 mg, capsules, administered orally, once daily for 8 weeks
|
|---|---|---|---|
|
Change From Baseline to Week 8 in Fatigue Severity Scale
|
-2.0 units on a scale
Standard Error 0.14
|
-1.8 units on a scale
Standard Error 0.19
|
-2.2 units on a scale
Standard Error 0.29
|
SECONDARY outcome
Timeframe: Up to 8 weeksPopulation: All participants randomized to LY2216684 included in the primary efficacy analysis with a pharmacokinetic (PK) sample at the participants' final study visit.
Predicted maximal LY2216684 plasma concentrations at steady state (Cmax,ss) are reported, using the dose at the last visit in the study for participants included in the primary efficacy analysis.
Outcome measures
| Measure |
LY2216684
n=193 Participants
LY2216684: flexible dose of 3, 6, 9, or 12 milligrams (mg), tablets, administered orally, once daily for 8 weeks
|
Placebo
Placebo: tablet and capsule equivalents to LY2216684 and escitalopram, respectively, administered orally, once daily for 8 weeks
|
Escitalopram
Escitalopram: flexible dose of 10 or 20 mg, capsules, administered orally, once daily for 8 weeks
|
|---|---|---|---|
|
Pharmacokinetics: Predicted Maximal Concentration of LY2216684 at Steady State (Cmax,ss) at Week 8 Endpoint
3 mg dose
|
10.5 nanograms per milliliter (ng/mL)
Standard Deviation 2.0
|
—
|
—
|
|
Pharmacokinetics: Predicted Maximal Concentration of LY2216684 at Steady State (Cmax,ss) at Week 8 Endpoint
6 mg dose
|
22.6 nanograms per milliliter (ng/mL)
Standard Deviation 5.4
|
—
|
—
|
|
Pharmacokinetics: Predicted Maximal Concentration of LY2216684 at Steady State (Cmax,ss) at Week 8 Endpoint
9 mg dose
|
32 nanograms per milliliter (ng/mL)
Standard Deviation 6.4
|
—
|
—
|
|
Pharmacokinetics: Predicted Maximal Concentration of LY2216684 at Steady State (Cmax,ss) at Week 8 Endpoint
12 mg dose
|
40.6 nanograms per milliliter (ng/mL)
Standard Deviation 9.9
|
—
|
—
|
SECONDARY outcome
Timeframe: Baseline through Week 8Population: All randomized participants.
The number of participants with at least one serious adverse event, regardless of causality is reported cumulatively through Week 8. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Event module.
Outcome measures
| Measure |
LY2216684
n=269 Participants
LY2216684: flexible dose of 3, 6, 9, or 12 milligrams (mg), tablets, administered orally, once daily for 8 weeks
|
Placebo
n=138 Participants
Placebo: tablet and capsule equivalents to LY2216684 and escitalopram, respectively, administered orally, once daily for 8 weeks
|
Escitalopram
n=62 Participants
Escitalopram: flexible dose of 10 or 20 mg, capsules, administered orally, once daily for 8 weeks
|
|---|---|---|---|
|
Number of Participants With at Least 1 Serious Adverse Event (Safety and Tolerability)
|
2 Participants
|
1 Participants
|
2 Participants
|
SECONDARY outcome
Timeframe: Baseline, Week 8Population: All randomized participants who received at least one dose of double-blind study drug and who had a baseline and at least one post-baseline HAMD-21 value.
The HAMD-21 is a 21-item assessment used to measure depression severity. Items were rated on a scale from 0 (symptoms not present) to a maximum of 2 to 4 (symptom extremely severe) for a total score ranging from 0 (not at all depressed) to 60 (severely depressed). Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, investigator, visit, baseline score, treatment-by-visit, and baseline score-by-visit.
Outcome measures
| Measure |
LY2216684
n=239 Participants
LY2216684: flexible dose of 3, 6, 9, or 12 milligrams (mg), tablets, administered orally, once daily for 8 weeks
|
Placebo
n=120 Participants
Placebo: tablet and capsule equivalents to LY2216684 and escitalopram, respectively, administered orally, once daily for 8 weeks
|
Escitalopram
n=52 Participants
Escitalopram: flexible dose of 10 or 20 mg, capsules, administered orally, once daily for 8 weeks
|
|---|---|---|---|
|
Change From Baseline to Week 8 in the 21-item Hamilton Depression Rating Scale (HAM-21) Total Score
|
-13.6 units on a scale
Standard Error 0.57
|
-13.0 units on a scale
Standard Error 0.79
|
-15.0 units on a scale
Standard Error 1.24
|
SECONDARY outcome
Timeframe: Baseline, up to week 8Population: All randomized participants who received at least one dose of double-blind study drug and who have a baseline and at least one post-baseline WLDRT value. Last observation carried forward (LOCF) methodology was used.
The WLDRT is a test of visual learning and recall. Participants are shown a series of words (commonly used nouns) and asked to say each of the words aloud, then are asked to recall the words and the total number of correct words recalled is recorded (possible score ranged from 0 to 15 words). The process is repeated 3 times. The Word List Learning Test score is calculated as the average number of words recalled during the first 3 trials. After a 30-minute delay, participants are again asked to recall the words, and the total number of correct words remembered after the delay is recorded as the Delayed Recall Test score. The baseline value was the last non-missing value before the first randomized double-blind study drug administration. Least Squares (LS) means were adjusted for treatment, investigator, and baseline score.
Outcome measures
| Measure |
LY2216684
n=207 Participants
LY2216684: flexible dose of 3, 6, 9, or 12 milligrams (mg), tablets, administered orally, once daily for 8 weeks
|
Placebo
n=107 Participants
Placebo: tablet and capsule equivalents to LY2216684 and escitalopram, respectively, administered orally, once daily for 8 weeks
|
Escitalopram
n=43 Participants
Escitalopram: flexible dose of 10 or 20 mg, capsules, administered orally, once daily for 8 weeks
|
|---|---|---|---|
|
Cognitive Assessment Battery: Change From Baseline in Word List Learning and Delayed Recall Test (WLDRT) up to Week 8 Endpoint
Word List Learning Test
|
0.5 number of correct words
Standard Error 0.15
|
0.3 number of correct words
Standard Error 0.19
|
0.3 number of correct words
Standard Error 0.28
|
|
Cognitive Assessment Battery: Change From Baseline in Word List Learning and Delayed Recall Test (WLDRT) up to Week 8 Endpoint
Delayed Recall Test
|
0.4 number of correct words
Standard Error 0.19
|
0.2 number of correct words
Standard Error 0.25
|
0.0 number of correct words
Standard Error 0.37
|
SECONDARY outcome
Timeframe: Baseline, up to Week 8Population: All randomized participants who received at least one dose of double-blind study drug and who had a baseline and at least one post-baseline SDST value. Last observation carried forward (LOCF) methodology was used.
The SDST is an attention-demanding psychomotor component based on the Digit Symbol Substitution Test from the Wechsler Adult Intelligence Scale. The participant is given a symbol/digit code in which each of the digits 1 through 9 is paired with a different symbol. Below the code, a series of symbols selected from those in the code are presented in an irregular order. The participant is instructed to write the number that is appropriate for each symbol in the space below each symbol and to complete as many correct digits as possible within a 90-second test period. For this test, the number of attempts and number of correct digits is collected. The percentage of correct digits is presented based on the number of correct digits divided by the number of attempts, multiplied by 100 (score ranged from 0 to 100% correct). Least squares (LS) means were adjusted for treatment, investigator, and baseline score.
Outcome measures
| Measure |
LY2216684
n=182 Participants
LY2216684: flexible dose of 3, 6, 9, or 12 milligrams (mg), tablets, administered orally, once daily for 8 weeks
|
Placebo
n=94 Participants
Placebo: tablet and capsule equivalents to LY2216684 and escitalopram, respectively, administered orally, once daily for 8 weeks
|
Escitalopram
n=39 Participants
Escitalopram: flexible dose of 10 or 20 mg, capsules, administered orally, once daily for 8 weeks
|
|---|---|---|---|
|
Cognitive Assessment Battery: Change From Baseline in Symbol Digit Substitution Test (SDST) up to Week 8 Endpoint
|
3.2 percentage of correct digits
Standard Error 1.12
|
2.5 percentage of correct digits
Standard Error 1.42
|
2.2 percentage of correct digits
Standard Error 2.10
|
SECONDARY outcome
Timeframe: Baseline, up to Week 8Population: All randomized participants who received at least one dose of double-blind study drug and who had a baseline and at least one post-baseline 2DCT value. Last observation carried forward (LOCF) methodology was used.
The Two Digit Cancellation Test (2DCT) is a clinical adaptation of the visual search tasks that have been used to investigate cognitive processes involved in attention and visual information processing. For this test, the participant is presented with a piece of paper containing rows of digits. At the top of the page are two target digits. The participant is instructed to examine each row of digits working from top to bottom and left to right crossing off each number that matches either of the two numbers at the top of the page. The number of targets hit, number of errors, and number of times the participant had to be reminded of the task are recorded for the 45-second test. The 2DCT composite cognitive score is calculated as the number of targets hit - number of errors - number of reminders. 2DCT score ranges 0-40 with higher score indicating better cognition. Least squares (LS) means were adjusted for treatment, investigator, and baseline score.
Outcome measures
| Measure |
LY2216684
n=194 Participants
LY2216684: flexible dose of 3, 6, 9, or 12 milligrams (mg), tablets, administered orally, once daily for 8 weeks
|
Placebo
n=99 Participants
Placebo: tablet and capsule equivalents to LY2216684 and escitalopram, respectively, administered orally, once daily for 8 weeks
|
Escitalopram
n=49 Participants
Escitalopram: flexible dose of 10 or 20 mg, capsules, administered orally, once daily for 8 weeks
|
|---|---|---|---|
|
Cognitive Assessment Battery: Change From Baseline in Two Digit Cancellation Test up to Week 8 Endpoint
|
0.8 units on a scale
Standard Error 0.62
|
1.2 units on a scale
Standard Error 0.83
|
1.0 units on a scale
Standard Error 1.26
|
SECONDARY outcome
Timeframe: Baseline, up to Week 8Population: All randomized participants who received at least one dose of double-blind study drug and who had a baseline and at least one post-baseline Trail Making A value. Last observation carried forward (LOCF) methodology was used.
Trail Making A is a neurocognitive test associated with general brain function. While being timed, the participant is instructed to connect 25 randomly placed circled numbers on a page in numerical sequence without lifting their pencil. If a participant makes a mistake, the mistake is pointed out and the participant must start again from the last correct circle. The total time to complete the task (up to 300 seconds, with a lower value indicating better brain function) is recorded. Least squares (LS) means were adjusted for treatment, investigator, and baseline score.
Outcome measures
| Measure |
LY2216684
n=203 Participants
LY2216684: flexible dose of 3, 6, 9, or 12 milligrams (mg), tablets, administered orally, once daily for 8 weeks
|
Placebo
n=104 Participants
Placebo: tablet and capsule equivalents to LY2216684 and escitalopram, respectively, administered orally, once daily for 8 weeks
|
Escitalopram
n=43 Participants
Escitalopram: flexible dose of 10 or 20 mg, capsules, administered orally, once daily for 8 weeks
|
|---|---|---|---|
|
Cognitive Assessment Battery: Change From Baseline in Trail Making A up to Week 8 Endpoint
|
-9.9 seconds
Standard Error 2.97
|
-11.1 seconds
Standard Error 3.85
|
-5.6 seconds
Standard Error 5.68
|
Adverse Events
LY2216684 Double Blind Phase
Placebo Double Blind Phase
Escitalopram Double Blind Phase
LY2216684 Discontinuation Phase
Placebo Discontinuation Phase
Escitalopram Discontinuation Phase
Serious adverse events
| Measure |
LY2216684 Double Blind Phase
n=269 participants at risk
LY2216684: 3, 6, 9, or 12 milligrams (mg) tablets, administered orally with flexible dosing, once daily for 8 weeks
|
Placebo Double Blind Phase
n=138 participants at risk
Placebo: tablet and capsule equivalents to LY2216684 and escitalopram, respectively, administered orally once daily for 8 weeks
|
Escitalopram Double Blind Phase
n=62 participants at risk
Escitalopram: 10 or 20 mg capsules, administered orally with flexible dosing, once daily for 8 weeks
|
LY2216684 Discontinuation Phase
n=269 participants at risk
Included all randomized participants who discontinued LY2216684 treatment
|
Placebo Discontinuation Phase
n=138 participants at risk
Included all randomized participants who discontinued placebo
|
Escitalopram Discontinuation Phase
n=62 participants at risk
Included all randomized participants who discontinued escitalopram treatment
|
|---|---|---|---|---|---|---|
|
Blood and lymphatic system disorders
Anaemia
|
0.37%
1/269 • Number of events 1
|
0.00%
0/138
|
0.00%
0/62
|
0.00%
0/269
|
0.00%
0/138
|
0.00%
0/62
|
|
Infections and infestations
Gastroenteritis
|
0.00%
0/269
|
0.72%
1/138 • Number of events 1
|
1.6%
1/62 • Number of events 1
|
0.00%
0/269
|
0.00%
0/138
|
0.00%
0/62
|
|
Infections and infestations
Malaria
|
0.00%
0/269
|
0.00%
0/138
|
1.6%
1/62 • Number of events 1
|
0.00%
0/269
|
0.00%
0/138
|
0.00%
0/62
|
|
Injury, poisoning and procedural complications
Near drowning
|
0.00%
0/269
|
0.00%
0/138
|
0.00%
0/62
|
0.00%
0/269
|
0.72%
1/138 • Number of events 1
|
0.00%
0/62
|
|
Psychiatric disorders
Depression
|
0.37%
1/269 • Number of events 1
|
0.00%
0/138
|
0.00%
0/62
|
0.00%
0/269
|
0.00%
0/138
|
0.00%
0/62
|
|
Psychiatric disorders
Suicide attempt
|
0.00%
0/269
|
0.00%
0/138
|
1.6%
1/62 • Number of events 1
|
0.00%
0/269
|
0.00%
0/138
|
0.00%
0/62
|
Other adverse events
| Measure |
LY2216684 Double Blind Phase
n=269 participants at risk
LY2216684: 3, 6, 9, or 12 milligrams (mg) tablets, administered orally with flexible dosing, once daily for 8 weeks
|
Placebo Double Blind Phase
n=138 participants at risk
Placebo: tablet and capsule equivalents to LY2216684 and escitalopram, respectively, administered orally once daily for 8 weeks
|
Escitalopram Double Blind Phase
n=62 participants at risk
Escitalopram: 10 or 20 mg capsules, administered orally with flexible dosing, once daily for 8 weeks
|
LY2216684 Discontinuation Phase
n=269 participants at risk
Included all randomized participants who discontinued LY2216684 treatment
|
Placebo Discontinuation Phase
n=138 participants at risk
Included all randomized participants who discontinued placebo
|
Escitalopram Discontinuation Phase
n=62 participants at risk
Included all randomized participants who discontinued escitalopram treatment
|
|---|---|---|---|---|---|---|
|
Gastrointestinal disorders
Constipation
|
6.7%
18/269 • Number of events 19
|
5.1%
7/138 • Number of events 7
|
1.6%
1/62 • Number of events 1
|
0.00%
0/269
|
0.00%
0/138
|
0.00%
0/62
|
|
Gastrointestinal disorders
Dry mouth
|
6.3%
17/269 • Number of events 17
|
4.3%
6/138 • Number of events 6
|
6.5%
4/62 • Number of events 4
|
0.00%
0/269
|
0.72%
1/138 • Number of events 1
|
0.00%
0/62
|
|
Gastrointestinal disorders
Nausea
|
8.9%
24/269 • Number of events 27
|
3.6%
5/138 • Number of events 5
|
11.3%
7/62 • Number of events 7
|
0.00%
0/269
|
0.00%
0/138
|
1.6%
1/62 • Number of events 1
|
|
Nervous system disorders
Headache
|
9.7%
26/269 • Number of events 34
|
6.5%
9/138 • Number of events 9
|
11.3%
7/62 • Number of events 7
|
0.74%
2/269 • Number of events 2
|
0.72%
1/138 • Number of events 1
|
1.6%
1/62 • Number of events 1
|
|
Psychiatric disorders
Insomnia
|
5.2%
14/269 • Number of events 15
|
2.9%
4/138 • Number of events 4
|
3.2%
2/62 • Number of events 2
|
0.74%
2/269 • Number of events 2
|
0.00%
0/138
|
0.00%
0/62
|
Additional Information
Chief Medical Officer
Eli Lilly and Company
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place
Restriction type: GT60